Latest news and press releases about Matinas BioPharma Holdings, Inc. (MTNB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts.
Price
| Price | $0.17 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.60 |
| EV / EBITDA | -0.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -181.45% |
| Return on Invested Capital | -323.22% |
| Return on Assets | -214.21% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · ADXN · BCLI · CDIO · HCWB · IBO
Explore sector: Healthcare · Biotechnology
More sections of MTNB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks